FMP

FMP

Enter

CVAC - CureVac N.V.

Financial Summary of CureVac N.V.(CVAC), CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformati

photo-url-https://financialmodelingprep.com/image-stock/CVAC.png

CureVac N.V.

CVAC

NASDAQ

CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202, a prophylactic mRNA-based vaccine, which has completed Phase 1 clinical trial for rabies virus glycoprotein; and CVSQIV, which is in Phase 1 clinical trial against influenza, as well as vaccine for lassa fever, yellow fever, respiratiory syncytial virus, rotavirus, malaria, and universal influenza. The company also develops RNA-based cancer immunotherapies, including CV8102, which is in Phase 1 clinical trial for treating cutaneous melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck. The company was founded in 2000 and is headquartered in Tübingen, Germany.

3.66 USD

0.1 (2.73%)

About

ceo

Dr. Alexander Zehnder M.B.A., M.D.

sector

Healthcare

industry

Biotechnology

exchange

NASDAQ

Description

CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202, a prophylactic mRNA-based vaccine, which has completed Phase 1 clinical trial for rabies virus glycoprotein; and CVSQIV, which is in Phase 1 clinical trial against influenza, as well as vaccine for lassa fever, yellow fever, respiratiory syncytial virus, rotavirus, malaria, and universal influenza. The company also develops RNA-based cancer immunotherapies, including CV8102, which is in Phas...

CIK

0001809122

ISIN

NL0015436031

CUSIP

N2451R105

Address

Friedrich-Miescher-Strasse 15

Phone

49 7071 9883 0

Country

DE

Employee

999

IPO Date

Aug 14, 2020

Summary

CIK

0001809122

Exchange

NASDAQ

Industry

Biotechnology

Sector

Healthcare

CUSIP

N2451R105

ISIN

NL0015436031

Country

DE

Price

3.66

Beta

2.64

Volume Avg.

1.35M

Market Cap

820.96M

Shares

-

52-Week

2.215-10.19

DCF

0

ROE

-

ROA

-

Operating Margin

-

Debt/Equity

-

P/E

-2.75

P/B

-

Website

https://www.curevac.com

Historical Prices

We are unable to load the chart at this time.

fmp-logo

Financial Statement

We are unable to load the chart at this time.

fmp-logo

Earnings

We are unable to load the chart at this time.

fmp-logo

Upgrades and Downgrades

We are unable to load this data!

fmp-logo

People Also Watch

page loading card

Latest CVAC News

It looks like there's no news available.

fmp-logo
FMP

FMP

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.
twitterlinkedinfacebookinstagram
2017-2024 © Financial Modeling Prep